Literature DB >> 14645861

Polymyositis associated with infliximab treatment for rheumatoid arthritis.

J Musiał, A Undas, M Celińska-Lowenhoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14645861     DOI： 10.1093/rheumatology/keg388

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  15 in total

1.  A case of inclusion body myositis responsive to prednisolone therapy.

Authors:  Rahul Kalla; Majella Soumakiyan; Stephen Tuck
Journal:  Clin Rheumatol       Date:  2008-12-06       Impact factor: 2.980

2.  Idiopathic inflammatory myopathy: treatment options.

Authors:  Stephen J DiMartino
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

3.  A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal:  Semin Arthritis Rheum       Date:  2017-10-16       Impact factor: 5.532

4.  Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.

Authors:  Yuki Ishikawa; Naoichiro Yukawa; Koichiro Ohmura; Yuji Hosono; Yoshitaka Imura; Daisuke Kawabata; Takaki Nojima; Takao Fujii; Takashi Usui; Tsuneyo Mimori
Journal:  Clin Rheumatol       Date:  2010-02-09       Impact factor: 2.980

Review 5.  Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

Authors:  Lorenzo Cavagna; Laura Nuño; Carlo Alberto Scirè; Marcello Govoni; Francisco Javier Lopez Longo; Franco Franceschini; Rossella Neri; Santos Castañeda; Walter Alberto Sifuentes Giraldo; Roberto Caporali; Florenzo Iannone; Enrico Fusaro; Giuseppe Paolazzi; Raffaele Pellerito; Andreas Schwarting; Lesley Ann Saketkoo; Norberto Ortego-Centeno; Luca Quartuccio; Elena Bartoloni; Christof Specker; Trinitario Pina Murcia; Renato La Corte; Federica Furini; Valentina Foschi; Javier Bachiller Corral; Paolo Airò; Ilaria Cavazzana; Julia Martínez-Barrio; Michelle Hinojosa; Margherita Giannini; Simone Barsotti; Julia Menke; Kostantinos Triantafyllias; Rosetta Vitetta; Alessandra Russo; Laura Bogliolo; Gianluigi Bajocchi; Elena Bravi; Giovanni Barausse; Roberto Bortolotti; Carlo Selmi; Simone Parisi; Fausto Salaffi; Carlomaurizio Montecucco; Miguel Angel González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 6.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

7.  A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept.

Authors:  Yuki Ishikawa; Naoichiro Yukawa; Daisuke Kawabata; Koichiro Ohmura; Takao Fujii; Takashi Usui; Tsuneyo Mimori
Journal:  Clin Rheumatol       Date:  2011-01-11       Impact factor: 2.980

8.  High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis.

Authors:  Ayako Nakajima; Koichiro Yoshino; Makoto Soejima; Yasushi Kawaguchi; Takashi Satoh; Masataka Kuwana; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2011-04-11       Impact factor: 2.631

Review 9.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 10.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.